ESC Premium Access

Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)

Congress Presentation

About the speaker

Doctor Essra Ridha

Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)
0 follower

22 more presentations in this session

Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Thumbnail

In-hospital mortality, length of stay and costs of treating atrial fibrillation or flutter patients admitted for intracranial hemorrhage

Speaker: Doctor E. Nguyen (Storrs, US)

Thumbnail

One-year permeability rate of left atrial appendage closure devices: high incidence of peridevice leak and lack of endothelialization

Speaker: Doctor G. Laugaudin (Montpellier, FR)

Thumbnail

Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation

Speaker: Professor J. Piccini (Durham, US)

Thumbnail

Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban

Speaker: Professor G. Lip (Liverpool, GB)

Thumbnail

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation II

Speakers: Doctor E. Ridha, Doctor A. Nissen Bonde, Doctor E. Nguyen, Doctor G. Laugaudin, Professor J. Piccini...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb